GH-axis research
IGF-1 LR3
Peptide di ricerca liofilizzato sulla segnalazione endocrina per la revisione dei sistemi
IGF-1 LR3 is a modified IGF-1 analog studied around IGF receptor signaling and altered binding-protein interaction.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca IGF-1 LR3
IGF-1 LR3 is a modified analog of insulin-like growth factor 1 designed with sequence changes that reduce interaction with IGF-binding proteins and alter experimental persistence. Cell and animal studies use it to examine IGF-1 receptor signaling, PI3K-AKT and MAPK pathways, proliferation, differentiation, glucose handling, and other growth-related endpoints. It is not interchangeable with endogenous IGF-1, full-length HGH, or upstream GH secretagogues. IGF-1 LR3 is generally selected for controlled cell-culture or receptor-pathway experiments that specifically require the long-R3 analog. Results can vary substantially with cell type, serum conditions, concentration, and exposure time, and the evidence base is primarily preclinical.
Molecular class
83-residue long-R3 IGF-1 analog
Sequence / composition
An IGF-1 analog with an Arg substitution at position 3 and a 13-residue amino-terminal extension.
Research design note
The long-R3 construct is used to alter binding-protein interaction relative to native 70-residue IGF-1.
Meccanismo proposto
A modified IGF-1 analog with an N-terminal extension and an amino-acid substitution that reduce affinity for IGF-binding proteins. The proposed result is greater free analog availability and prolonged activation of IGF-1R, PI3K-AKT, and MAPK signaling.
Effetti riportati negli studi
- Cell studies report increased proliferation, survival signaling, differentiation, protein synthesis, and glucose uptake in responsive cell types.
- Animal and agricultural-model studies report growth and metabolic effects that vary with tissue, dose, and exposure.
- Prolonged mitogenic signaling, hypoglycemia-related effects, and uncontrolled cell growth are important experimental concerns.
Endpoint di ricerca comuni
IGF-1R phosphorylation, AKT and ERK signaling, proliferation, apoptosis, differentiation, protein synthesis, glucose uptake, binding-protein interaction, and exposure duration.
Evidenze e limiti
Evidence is predominantly cell and animal based. IGF-1 LR3 is not equivalent to endogenous IGF-1, and established human safety data are lacking.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.